Alnylam Pharmaceuticals Inc. (ALNY)

85.00
2.80 3.20
NASDAQ : Health Technology
Prev Close 87.82
Open 87.95
Day Low/High 84.95 / 87.97
52 Wk Low/High 60.27 / 96.14
Volume 273.12K
Avg Volume 696.90K
Exchange NASDAQ
Shares Outstanding 111.21M
Market Cap 9.43B
EPS -7.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
Alnylam To Webcast Presentation At Leerink Partners Rare Disease Roundtable

Alnylam To Webcast Presentation At Leerink Partners Rare Disease Roundtable

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Leerink Partners Rare Disease Roundtable on Wednesday,...

Alnylam Initiates DISCOVERY, A Screening Study Examining The Prevalence Of Transthyretin (TTR) Mutations In Patients Suspected Of Having Cardiac Amyloidosis

Alnylam Initiates DISCOVERY, A Screening Study Examining The Prevalence Of Transthyretin (TTR) Mutations In Patients Suspected Of Having Cardiac Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated its DISCOVERY trial, a screening study examining the prevalence of transthyretin (TTR) ...

Alnylam To Webcast Presentation At 21st Annual NewsMakers In The Biotech Industry Conference

Alnylam To Webcast Presentation At 21st Annual NewsMakers In The Biotech Industry Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 21 st Annual NewsMakers in the Biotech Industry...

Alnylam Presents New Pre-Clinical Data With ALN-CC5, A Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 In Development For The Treatment Of Complement-Mediated Diseases

Alnylam Presents New Pre-Clinical Data With ALN-CC5, A Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 In Development For The Treatment Of Complement-Mediated Diseases

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today new pre-clinical results with ALN-CC5, a subcutaneously administered RNAi therapeutic targeting complement ...

Alnylam Strengthens Management Team With New Key Appointments

Alnylam Strengthens Management Team With New Key Appointments

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the expansion of its management team with the appointments of Karen Anderson as Senior Vice President, Chief Human ...

Alnylam Broadens Pipeline With ALN-AGT, A Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen (AGT) For The Treatment Of Hypertensive Disorders Of Pregnancy (HDP), Including Preeclampsia

Alnylam Broadens Pipeline With ALN-AGT, A Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen (AGT) For The Treatment Of Hypertensive Disorders Of Pregnancy (HDP), Including Preeclampsia

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it is broadening its pipeline with ALN-AGT, a subcutaneously administered RNAi therapeutic targeting ...

Alnylam To Webcast Presentation At Morgan Stanley Global Healthcare Conference

Alnylam To Webcast Presentation At Morgan Stanley Global Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Morgan Stanley Global Healthcare Conference on...

Alnylam Receives Notice Of Allowance From United States Patent And Trademark Office (USPTO) For New Patent Broadly Covering RNAi-Mediating, Double-Stranded Molecules Of 19 To 52 Nucleotides In Length

Alnylam Receives Notice Of Allowance From United States Patent And Trademark Office (USPTO) For New Patent Broadly Covering RNAi-Mediating, Double-Stranded Molecules Of 19 To 52 Nucleotides In Length

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for claims in the Tuschl...

Alnylam Pharmaceuticals Larger Than S&P 500 Component GameStop

Alnylam Pharmaceuticals Larger Than S&P 500 Component GameStop

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Alnylam Pharmaceuticals Inc was identified as having a larger market cap than the smaller end of the S&P 500, for example GameStop Corp , according to The Online Investor. Market capitalization is an important data point for investors to keep an eye on, for various reasons.

Alnylam Receives Notice Of Allowance From United States Patent And Trademark Office (USPTO) For New Patent Broadly Covering RNAi-Mediating Double-Stranded Molecules Comprising Up To 25 Base Pairs

Alnylam Receives Notice Of Allowance From United States Patent And Trademark Office (USPTO) For New Patent Broadly Covering RNAi-Mediating Double-Stranded Molecules Comprising Up To 25 Base Pairs

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for claims in the Tuschl...

Alnylam Pharmaceuticals Reports Second Quarter 2014 Financial Results And Highlights Recent Period Activities

Alnylam Pharmaceuticals Reports Second Quarter 2014 Financial Results And Highlights Recent Period Activities

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2014, and company highlights.

Alnylam Receives Orphan Drug Designations In The European Union For ALN-AT3, An RNAi Therapeutic In Development For The Treatment Of Hemophilia

Alnylam Receives Orphan Drug Designations In The European Union For ALN-AT3, An RNAi Therapeutic In Development For The Treatment Of Hemophilia

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted Orphan Drug ...

Biotech Stock Mailbag: Arrowhead, Catalyst Pharma

Biotech Stock Mailbag: Arrowhead, Catalyst Pharma

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Alnylam To Webcast Conference Call Discussing Second Quarter 2014 Financial Results

Alnylam To Webcast Conference Call Discussing Second Quarter 2014 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the second quarter ending June 30, 2014 on Thursday, August 7, 2014, after ...

Alnylam To Host Additional Events In “RNAi Roundtable” Webcast Series

Alnylam To Host Additional Events In “RNAi Roundtable” Webcast Series

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it has added three new events to its series of online “RNAi Roundtables” that it is hosting...

Alnylam Receives Notice Of Allowance From United States Patent And Trademark Office (USPTO) For New Patent Broadly Covering Conjugate-Based Delivery Of RNA Therapeutics

Alnylam Receives Notice Of Allowance From United States Patent And Trademark Office (USPTO) For New Patent Broadly Covering Conjugate-Based Delivery Of RNA Therapeutics

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for claims in the ...

Alnylam To Host “RNAi Roundtable” Webcast Series

Alnylam To Host “RNAi Roundtable” Webcast Series

Alnylam Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it plans to host and webcast a series of online “RNAi Roundtables” during July and August.

Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Perilous Reversal" Stock

Trade-Ideas: Alnylam Pharmaceuticals (ALNY) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "perilous reversal" (up big yesterday but down big today) candidate

Alnylam Elects Amy Schulman To Its Board Of Directors

Alnylam Elects Amy Schulman To Its Board Of Directors

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the election of Amy W.

Alnylam Added To Russell 1000 Index As A Member Of The Large-Cap Segment Of The U.S. Equity Universe

Alnylam Added To Russell 1000 Index As A Member Of The Large-Cap Segment Of The U.S. Equity Universe

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has been added to the Russell 1000 Index, effective June 27, 2014.

Alnylam And The Alpha-1 Project (TAP) Form Collaboration For Advancement Of ALN-AAT, An RNAi Therapeutic In Development For The Treatment Of Alpha-1 Antitrypsin (AAT) Deficiency-Associated Liver Disease (Graphic: Business Wire)

Alnylam And The Alpha-1 Project (TAP) Form Collaboration For Advancement Of ALN-AAT, An RNAi Therapeutic In Development For The Treatment Of Alpha-1 Antitrypsin (AAT) Deficiency-Associated Liver Disease (Graphic: Business Wire)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and The Alpha-1 Project (TAP), the venture philanthropy subsidiary of the Alpha-1 Foundation, announced today that they have ...

Alnylam To Webcast Presentation At 9th Annual JMP Securities Healthcare Conference

Alnylam To Webcast Presentation At 9th Annual JMP Securities Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the 9 th Annual JMP Securities Healthcare Conference on ...

Alnylam Announces United States Patent And Trademark Office (USPTO) Issues Patent Covering RNAi Therapeutics For The Treatment Of Hepatitis B Virus (HBV) Infection

Alnylam Announces United States Patent And Trademark Office (USPTO) Issues Patent Covering RNAi Therapeutics For The Treatment Of Hepatitis B Virus (HBV) Infection

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued a new patent (U.

Alnylam Presents New Pre-Clinical Data With Development Candidate For ALN-CC5, A Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 In Development For The Treatment Of Complement-Mediated Diseases

Alnylam Presents New Pre-Clinical Data With Development Candidate For ALN-CC5, A Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 In Development For The Treatment Of Complement-Mediated Diseases

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today new pre-clinical results with its Development Candidate (DC) for ALN-CC5, a subcutaneously administered ...

Alnylam To Webcast Presentation At Goldman Sachs 35th Annual Global Healthcare Conference

Alnylam To Webcast Presentation At Goldman Sachs 35th Annual Global Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Goldman Sachs 35 th Annual Global Healthcare Conference ...

Alnylam Pharmaceuticals (ALNY) In A Perilous Reversal

Alnylam Pharmaceuticals (ALNY) In A Perilous Reversal

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "perilous reversal" (up big yesterday but down big today) candidate

Alnylam Pharmaceuticals Larger Than S&P 500 Component Graham Holdings

Alnylam Pharmaceuticals Larger Than S&P 500 Component Graham Holdings

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Alnylam Pharmaceuticals Inc was identified as having a larger market cap than the smaller end of the S&P 500, for example Graham Holdings Co. , according to The Online Investor.

Today's Dead Cat Bounce Stock: Alnylam Pharmaceuticals (ALNY)

Today's Dead Cat Bounce Stock: Alnylam Pharmaceuticals (ALNY)

Trade-Ideas LLC identified Alnylam Pharmaceuticals (ALNY) as a "dead cat bounce" (down big yesterday but up big today) candidate

Alnylam And Collaborators Publish Pre-Clinical Results With ALN-AS1, An RNAi Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) For The Treatment Of Hepatic Porphyrias, In The Proceedings Of The National Academy Of Sciences

Alnylam And Collaborators Publish Pre-Clinical Results With ALN-AS1, An RNAi Therapeutic Targeting Aminolevulinic Acid Synthase-1 (ALAS-1) For The Treatment Of Hepatic Porphyrias, In The Proceedings Of The National Academy Of Sciences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the publication in the Proceedings of the National Academy of Sciences (PNAS) of pre-clinical results with ...

Alnylam Reports Initial Positive Top-Line Data From Phase 1 Clinical Trial With ALN-AT3, An RNAi Therapeutic Targeting Antithrombin (AT) In Development For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)

Alnylam Reports Initial Positive Top-Line Data From Phase 1 Clinical Trial With ALN-AT3, An RNAi Therapeutic Targeting Antithrombin (AT) In Development For The Treatment Of Hemophilia And Rare Bleeding Disorders (RBD)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today positive top-line results from its ongoing Phase 1 trial of ALN-AT3, a subcutaneously administered RNAi therapeutic ...